Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Sudden death after 125I brachytherapy in prostate cancer patient: a case report].
Kimura M, Satoh T, Fujita T, Okusa H, Matsumoto K, Iwamura M, Kitano M, Ishiyama H, Hayakawa K, Okayasu I, Baba S. Kimura M, et al. Among authors: ishiyama h. Nihon Hinyokika Gakkai Zasshi. 2005 Jul;96(5):560-3. doi: 10.5980/jpnjurol1989.96.560. Nihon Hinyokika Gakkai Zasshi. 2005. PMID: 16083034 Free article. Japanese.
Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
Satoh T, Ishiyama H, Matsumoto K, Tsumura H, Kitano M, Hayakawa K, Ebara S, Nasu Y, Kumon H, Kanazawa S, Miki K, Egawa S, Aoki M, Toya K, Yorozu A, Nagata H, Saito S, Baba S. Satoh T, et al. Among authors: ishiyama h. BJU Int. 2009 Apr;103(8):1064-8. doi: 10.1111/j.1464-410X.2008.08234.x. Epub 2008 Nov 25. BJU Int. 2009. PMID: 19040526
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H, Kitano M, Satoh T, Kotani S, Uemae M, Matsumoto K, Okusa H, Tabata K, Baba S, Hayakawa K. Ishiyama H, et al. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):23-8. doi: 10.1016/j.ijrobp.2008.11.006. Epub 2009 Feb 23. Int J Radiat Oncol Biol Phys. 2009. PMID: 19243900
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H, Satoh T, Ishiyama H, Tabata K, Kotani S, Minamida S, Kimura M, Fujita T, Matsumoto K, Kitano M, Hayakawa K, Baba S. Tsumura H, et al. Among authors: ishiyama h. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92. doi: 10.1016/j.ijrobp.2011.04.026. Epub 2011 Jun 12. Int J Radiat Oncol Biol Phys. 2011. PMID: 21664068 Clinical Trial.
The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer.
Ikeda M, Matsumoto K, Niibe Y, Satoh T, Fujita T, Iwamura M, Ishiyama H, Kotani S, Hayakawa K, Baba S. Ikeda M, et al. Among authors: ishiyama h. J Radiat Res. 2011;52(5):674-9. doi: 10.1269/jrr.11036. Epub 2011 Sep 1. J Radiat Res. 2011. PMID: 21881297 Free article. Clinical Trial.
EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy.
Kurosaka S, Satoh T, Chow E, Asano Y, Tabata K, Kimura M, Tsumura H, Matsumoto K, Ishiyama H, Inoue Y, Hayakawa K, Baba S. Kurosaka S, et al. Among authors: ishiyama h. Ann Nucl Med. 2012 Jul;26(6):485-91. doi: 10.1007/s12149-012-0598-z. Epub 2012 Apr 3. Ann Nucl Med. 2012. PMID: 22477263 Clinical Trial.
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
Ishiyama H, Satoh T, Kitano M, Tabata K, Komori S, Ikeda M, Soda I, Kurosaka S, Sekiguchi A, Kimura M, Kawakami S, Iwamura M, Hayakawa K. Ishiyama H, et al. J Radiat Res. 2014 May;55(3):509-17. doi: 10.1093/jrr/rrt128. Epub 2013 Nov 11. J Radiat Res. 2014. PMID: 24222312 Free PMC article. Clinical Trial.
A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy.
Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K, Sekiguchi A, Takahashi R, Soda I, Takenaka K, Iwamura M, Hayakawa K. Ishiyama H, et al. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):134-9. doi: 10.1016/j.ijrobp.2014.05.009. Epub 2014 Jun 28. Int J Radiat Oncol Biol Phys. 2014. PMID: 24986744 Clinical Trial.
Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy.
Ishiyama H, Satoh T, Yorozu A, Saito S, Kataoka M, Hashine K, Nakamura R, Tanji S, Masui K, Okihara K, Ohashi T, Momma T, Aoki M, Miki K, Kato M, Morita M, Katayama N, Nasu Y, Kawanaka T, Fukumori T, Ito F, Shiroki R, Baba Y, Inadome A, Yoshioka Y, Takayama H, Hayakawa K. Ishiyama H, et al. J Radiat Res. 2016 Jan;57(1):68-74. doi: 10.1093/jrr/rrv065. Epub 2015 Oct 22. J Radiat Res. 2016. PMID: 26494116 Free PMC article.
Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.
Tsumura H, Satoh T, Ishiyama H, Tabata K, Komori S, Sekiguchi A, Ikeda M, Kurosaka S, Fujita T, Kitano M, Hayakawa K, Iwamura M. Tsumura H, et al. Among authors: ishiyama h. J Contemp Brachytherapy. 2016 Apr;8(2):95-103. doi: 10.5114/jcb.2016.59686. Epub 2016 Apr 29. J Contemp Brachytherapy. 2016. PMID: 27257412 Free PMC article.
Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
Ishiyama H, Kamitani N, Kawamura H, Kato S, Aoki M, Kariya S, Matsumura T, Kaidu M, Yoshida K, Hashimoto Y, Noda Y, Lim KHC, Kawase T, Takahashi T, Inaba K, Kumano M, Yoshikawa N, Yoshioka Y, Nakamura K, Hiratsuka J, Itami J, Hayakawa K. Ishiyama H, et al. Brachytherapy. 2017 May-Jun;16(3):503-510. doi: 10.1016/j.brachy.2017.01.006. Epub 2017 Feb 17. Brachytherapy. 2017. PMID: 28222973
Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy.
Kawakami S, Ishiyama H, Satoh T, Tsumura H, Sekiguchi A, Takenaka K, Tabata KI, Iwamura M, Hayakawa K. Kawakami S, et al. Among authors: ishiyama h. J Contemp Brachytherapy. 2017 Aug;9(4):316-322. doi: 10.5114/jcb.2017.69807. Epub 2017 Aug 30. J Contemp Brachytherapy. 2017. PMID: 28951750 Free PMC article.
A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial.
Ishiyama H, Tsumura H, Kawakami S, Satoh T, Sekiguchi A, Tabata KI, Iwamura M, Hayakawa K. Ishiyama H, et al. J Contemp Brachytherapy. 2018 Feb;10(1):10-16. doi: 10.5114/jcb.2018.74319. Epub 2018 Feb 28. J Contemp Brachytherapy. 2018. PMID: 29619051 Free PMC article.
Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS).
Koga H, Naito S, Ishiyama H, Yorozu A, Saito S, Kojima S, Higashide S, Kikuchi T, Nakamura K, Dokiya T, Fukushima M; J-POPS Study Group. Koga H, et al. Among authors: ishiyama h. Brachytherapy. 2019 Nov-Dec;18(6):806-813. doi: 10.1016/j.brachy.2019.06.006. Epub 2019 Aug 1. Brachytherapy. 2019. PMID: 31378511
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T, Hosotani S, Soda I, Ozawa T, Kusuhara S, Kakegawa MI, Kasajima M, Hiyoshi Y, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Ishiyama H, Naoki K. Fukui T, et al. Among authors: ishiyama h. Thorac Cancer. 2020 Apr;11(4):1005-1014. doi: 10.1111/1759-7714.13357. Epub 2020 Feb 14. Thorac Cancer. 2020. PMID: 32057187 Free PMC article.
Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Takezawa Y, Fujimoto H, Yokomizo A, Kakimoto KI, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer Investigators. Ito K, et al. Among authors: ishiyama h. Cancer. 2020 Sep 1;126(17):3961-3971. doi: 10.1002/cncr.33034. Epub 2020 Jun 23. Cancer. 2020. PMID: 32573779 Free article. Clinical Trial.
Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto KI, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators. Yokomizo A, et al. Among authors: ishiyama h. Cancer Med. 2021 May;10(10):3240-3248. doi: 10.1002/cam4.3895. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932114 Free PMC article. Clinical Trial.
233 results